Complement activation plays a critical role in controlling inflammatory responses. To assess the role of complement during ovarian cancer progression, we crossed two strains of mice with genetic complement deficiencies with transgenic mice that develop epithelial ovarian cancer (TgMISIIR-TAg). TgMISIIR-TAg mice fully or partially deficient for complement factor 3 (C3) (Tg + C3 KO 
) develop either no ovarian tumors or tumors that were small and poorly vascularized compared to wild-type littermates ( 
Introduction
Tumor development is a multistep process of cumulative genetic alterations that lead to cell autonomy. Inflammatory mechanisms are thought to play a critical role in this process [1, 2] . Lung, skin, gastrointestinal, liver, urinary, cervical, and ovarian cancers are all associated with chronic inflammation, and attenuating such inflammation has proved beneficial in the clinical setting [3] [4] [5] . Epithelial ovarian cancer (EOC), the fifth leading cause of cancer death among women in the United States, is also intimately related to inflammation. Incessant ovulation, a purported cause of malignant transformation in the ovarian surface epithelium, is associated with the activation of cytokine networks and repair mechanisms in ovarian stroma, whereas pelvic inflammatory conditions, including endometriosis, predict an increased risk of ovarian cancer [6, 7] . An early increase in serum inflammatory cytokines is detected in ovarian cancer patients [8] , and ovarian tumors and ascites are characterized by a brisk inflammatory milieu [9] [10] [11] . Finally, elevated levels of complement anaphylatoxins suggestive of local complement activation have been observed in ovarian cancer patients' ascites [12] . The complement system is comprised of serum proteins, membrane-bound receptors, and regulatory proteins [13, 14] . Its effector functions in host defense and inflammation are mediated mainly through the sequential activation and proteolytic cleavage of a series of serum proteins. Complement activation occurs through three distinct activation routes, the alternative, classic, and lectin pathways, all of which converge at a critical step: the activation of complement factor 3 (C3) by C3 convertase-mediated cleavage [14] . Complement functions include pathogen opsonization, inflammation mediated by C3a and C5a complement anaphylatoxins, and cytolysis resulting from the assembly of the membrane attack complex on targeted cells. Eliminating C3 prevents complement cascade activation and the generation of complement effectors that mediate a wide array of functions [13] [14] [15] . We demonstrated a role for complement activation in promoting the growth of transplanted tumors through myeloid-derived suppressor cell (MDSC) recruitment and activation in mice [16] , but the role of complement in early oncogenic events remains unknown.
Complement proteins are well established as important effectors in pathologic neovascularization in age-related macular degeneration (AMD [17] ), diabetic retinopathy, and retinopathy of prematurity [18] , as well as in the regulation of the angiogenic factors required for normal placental development [19, 20] . AMD involves a process whereby inappropriate angiogenesis in the choroid causes vascular invasion into the adjacent retina (choroidal neovascularization); preclinical models of AMD directly link complement to this process as complement components C3a and C5a promote choroidal neovascularization [21] and C5a increases vascular endothelial growth factor (VEGF) secretion of human retinal pigment epithelial cells [17] . Neovascularization is also a critical contributor to solid tumor progression, including cases of ovarian cancer [22] . VEGF, first identified as a vascular permeability factor secreted by tumor cells [23] , plays a principal role in angiogenesis by stimulating migration and proliferation of endothelial cells (ECs) and the expression of angiogenesis-related genes in ECs. Alternative splicing of the VEGF gene gives rise to multiple isoforms, including 121, 165, 189, and 206 amino acid long products that are differentially expressed in a variety of human tissues and tumors [24, 25] . Individual VEGF isoforms may differentially contribute to tumor vascularization according to the gradient model of Grunstein et al. [26] [27] [28] [29] ; in a breast cancer xenograft model, VEGF 121 was described as the most potent tumor angiogenic factor; and soluble VEGF 189 expression in human colon, renal, and lung cancers was strongly associated with increased microvessels, cancer metastasis, and poor prognosis [30, 31] . Notably, high levels of VEGF 165 have been associated with reduced survival in ovarian cancer [32] , and a phase 3 clinical trial showed that Bevacizumab, a humanized monoclonal antibody (mAb) that inhibits VEGF-A, improves progressionfree survival in women with ovarian cancer [33] . Although both complement activation and neo-angiogenesis play critical roles for ovarian cancer development, direct effects of complement activation on tumor neo-angiogenesis remain poorly understood.
To address this gap in knowledge, we crossed C3-deficient (C3 KO ) mice [34] or complement factor 5a receptor-deficient (C5aR KO ) mice [35] with C57BL/6 TgMISIIR-TAg transgenic mice that spontaneously develop EOC [36] [37] [38] . The immediate-early region of the SV40 virus that contains the oncogenic large and small T-antigen genes (TAg and tag, respectively) has been extensively used in the development of transgenic mouse models of cancer [39] [40] [41] [42] . SV40-TAg models have revealed much about tumor biology, permitting significant advancements in the understanding of the "angiogenic switch" [43] [44] [45] and tumor progression and invasion [46] . Expression of TAg results in the functional inactivation of the critical tumor suppressor proteins p53 and Rb. In fact, mutation and/or loss of TP53 is the most frequent genetic alteration identified in EOC, particularly the serous subtype [47, 48] , and mutation and/or loss of Rb and its downstream signaling mediators is also common [36, 37, 49, 50] . Consistent with this fact, the expression of SV40 under the transcriptional control of the Müllerian inhibiting substance type II receptor (MISIIR) gene promoter triggers spontaneous ovarian cancer development in transgenic mice. SV40 TAg-induced ovarian cancer closely resembles the histotype of serous EOC, the most common EOC histotype in humans [36] . We report that C3 and C5aR deficiencies resulted in profoundly impaired EOC growth, reduced tumor vascularization, and inhibition of specific VEGF isoforms, revealing a novel mechanism of VEGF regulation by complement anaphylatoxin C5a.
Materials and Methods

Mice
All mouse experiments were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania and conducted according to guidelines of the National Institutes of Health. C57BL/6 TgMISIIR-TAg transgenic mice [36] ) were then crossed with females homozygous for C3 or C5aR. The litters were sparse and small (less than or equal to five pups), consistent with an earlier report describing early pregnancy impairment in C3 KO mice [51] . Genotyping was performed by polymerase chain reaction (PCR) using previously described primers [35, 36] (Figure W1 , E and F).
Immunohistochemistry and Immunofluorescence
Ovaries and ovarian tumors were collected from 16-week-old mice and preserved in optimal cutting temperature (OCT) media embedding (Tissue-Tek; Sakura Finetek USA, Torrance, CA). Sections (8 μm) were cut, air-dried for 1 hour at room temperature, and fixed by immersion in cold 100% acetone for 5 minutes. After two washes in phosphatebuffered saline (PBS), slides were blocked with goat serum (Vector Labs, Burlingame, CA). ECs were stained with a rat anti-mouse CD31 mAb (BD Pharmingen, San Jose, CA) followed by biotinylated polyclonal goat anti-rat IgG (BD Pharmingen) and detected with the VectaStain ABC reagent and DAB (Vector Labs). Microvessels were defined as any dark-stained ECs or cell clusters clearly separated from adjacent structures, tumor cells, and other connective tissue elements. Microvascular density was expressed as the number of vessels per field of view. C3 deposition was detected with a rat anti-mouse C3b/iC3b/C3c mAb (2/11; HyCult) followed by Alexa 488-labeled goat anti-rat anti-IgG1 mAb (Invitrogen). The values reported reflect C3b/iC3b deposition per cell, averaged from five field-of-view tumors. Adjacent sections were stained with hematoxylin and eosin for histopathologic evaluation.
Cell Preparation and Antibodies
Ovaries and ovarian tumors from WT, TgMISIIR-TAg, Tg For intracellular analysis of cytokines, single-cell suspensions of whole mouse tumor (5 × 10 6 ) were first cultured for 24 hours at 37°C in 5% CO 2 . Cells were then resuspended in fresh medium with 0.002% 2-β-mercaptoethanol (Sigma, St Louis, MO) for 4 hours in 5% CO 2 . In some cases, cells were stimulated with lipopolysaccharide (LPS; 1 μg/ml) and IFN-γ (10 ng/ml) plus monensin (4 μl/6 ml of cell culture). For T-cell activation, 20 μl of anti-CD3/anti-CD28 activation beads were added per milliliter of culture as recommended by the manufacturer (Miltenyi, Auburn, CA).
In Vivo Angiogenic Assays
Growth factor-reduced Matrigel was mixed at 4°C (liquid state) at a 1:1 ratio with 10 ng/ml VEGF-A human recombinant homodimer protein (Millipore, Billerica, MA) or PBS as negative control. C57BL/6 WT mice were injected with 100 μl of each mixture in the right and left flanks. Animals were sacrificed 2 weeks after injection. Matrigel plugs were excised and digested with 1 mg/ml collagenase II and 10,000 U/ml DNAse I (Sigma) for 30 minutes at room temperature, as described [52] , then resuspended in PBS and analyzed by flow cytometry for the expression of CD31 and CD144.
Tube Formation
Tube formation assays measure the ability of ECs to form capillarylike tubes. Human mammary epithelial cells (HMECs; 2 × 10 6 ) at passages 2 to 6 were cultured in a T75 cm 2 flask in HMEC medium [MDCB131 medium (Gibco) supplemented with 10% (vol/vol) FBS, 1% penicillin/streptomycin, 100 μg/ml endothelial cell growth supplement (ECGS), and heparin (Sigma)]. The following day, cells were starved for 1 hour in MDCB131 medium and then harvested, and 2 × 10 5 cells/well were incubated in Matrigel 24-well plates (BD) with 2 nM C5a native protein or human recombinant proteins VEGF-A (VEGF 165 homodimer) at 2 ng/ml, VEGF 165 single domain (35.0 MWt, Peprotech, Rocky Hill, NJ) at 2 ng/ml (57 nM) or 2.7 ng/ml (77 nM), or VEGF 121 single domain (25.4 MWt, Peprotech) at 2 ng/ml (78 nM), in the presence or absence of 100 × PMX53 (AcF[OPdChaWR]) or of a chemically similar control peptide (AcF[OPdChaA(d)R]) that lacks functional properties. Plates were incubated at 37°C for 4 hours and endothelial tube formation was examined using a light microscope (Nikon, Melville, NY) at ×10 magnification. Tube formation per area was analyzed using ImagePro software (Media Cybernetics, Rockville, MD). Experiments were repeated three times.
VEGF Isoform-specific Reverse Transcription-PCR
RNAs were extracted using Trizol reagent from 2 × 10 5 HMECs or from single-cell suspension of mouse organs. HMECs were cultured at 2 × 10 5 cells/well in HMEC medium alone or supplemented with C5a native protein (10,400 MWt, CompTech, Tyler, TX) at 2 nM (20.8 ng/ml), and/or VEGF-A (1 ng/ml), with or without PMX53 C5a inhibitor or PMX53 control peptide in 12-well plates for 24 hours. Mouse spleen, liver, and bone marrow tissues were collected from C57BL/6, C3 KO , or C5aR KO mice. mRNAs were reverse transcribed using M-MLV Reverse Transcriptase (Promega, Madison, WI). Human and mouse VEGFs, human β 2 -microglobulin, and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers and PCR conditions were used as described [53] . Densitometry analysis was performed using ImageJ software (Image processing and analysis in Java) freely available from the National Institutes of Health at http://rsb.info.nih. gov/ij. Experiments were repeated three times.
Statistical Analyses
The data from experiments with two groups were analyzed using Student's t test and data from experiments with more than two groups were analyzed using one-way analysis of variance (ANOVA) using Satterthwaite and Welch adjustments for unequal variances, respectively. RNA expression and percentages of cells by type were transformed using the natural logarithm before their analysis. When the ANOVA was significant, pairwise comparisons were evaluated using Tukey procedure. Statistical significance was reached at P < .05. Analyses were performed using SAS software, version 9.2 (SAS Institute, Inc, Wayne, PA).
Results
Genetic C3 Deficiency Impairs Ovarian Tumor Development and Growth
In a transplanted tumor model, we have previously characterized the spontaneous activation of complement in the tumor vasculature and stroma, as evidenced by tumor-specific deposition of the C3 cleavage products C3b/iC3b in tumor-bearing mice [16] . To determine whether complement also plays a role during early spontaneous tumor formation, we crossed C3 KO Figure 1A ) with no visible microscopic tumors ( Figure W1 ). In addition, tumors that developed in Tg + C3 KO HET tumor volumes were not significantly different from each other (P = .279) ( Figure 1A ). Tg + C3 KO mice were unable to produce HET mice (gray bars; n = 4) were dissociated and stained for CD45, CD11b, B220, F480, GR1, CD3, CD8, CD4, CD25, and FoxP3. CD45 + leukocytes were gated and macrophages were identified as CD11b to the fact that Tg + C3 KO mice bore no, or only very small, ovarian tumors with a sparse amount of tumor cell infiltrates ( Figure 1D) WT littermates were then functionally characterized by flow cytometry. In the absence of stimulation (Figure 2 , B-E , white bars), no difference were noticed among the two groups in the percentages of macrophages expressing IL-12 ( Figure 2B , P = .948) or IL-10 ( Figure 2C , P = .447), of B cells expressing IL-10 ( Figure 2D , P = .092), or of CD8 + T cells expressing IFN-γ ( Figure 2E , P = .765). However, after a short stimulation with LPS and IFN-γ (Figure 2 , B-D, black bars) or with anti-CD3 and anti-CD28 ( Figure 2E , gray bars), the percentages of macrophages producing IL-12 (Figure 2B , P = .034) or IL-10 ( Figure 2C , P = .001), of B cells producing IL-10 ( Figure 2D , P = .0043), or of T cells producing IFN-γ ( Figure 2E , P = .0038) were significantly lower in Tg + C3 HET mice than in Tg + C3 WT mice. We thus concluded that C3 deficiency was associated with dampened cellular effector mechanisms in the ovarian tumor microenvironment. This suggested that alternate mechanisms besides cell-mediated immune rejection were likely mainly responsible for the decrease in tumor incidence and growth observed in Tg + C3 KO mice.
Genetic C3 Deficiency Impairs Tumor Vascularization and In Vivo EC Function
In preclinical models of AMD, deficiencies of C3a or C5a receptors result in decreased choroidal neovascularization and VEGF levels. Similar observations were reported when WT mice were treated with C3aR and C5aR antagonists, or neutralizing antibodies against C3a and C5a [21] , suggesting an important role for complement in modulating vascularization. In humans, the number of chronically activated tumor-infiltrating innate immune cells is positively correlated with blood vessel density [54] , while the attenuation of innate immunity in premalignant tissues reduces angiogenesis and limits tumor development in murine models [55] . We therefore asked whether defective angiogenesis was responsible for the reduced tumor formation in our model. HET littermates ( Figure 3A , P = .023), suggesting a functional role of complement for ECs. To address whether genetic (2, 7, 12) , or VEGF 121 (3, 8, 13) , or 2 nM C5a (4, 9, 14) in the presence of 200 ng/ml PMX53 (6-10) or PMX53 control peptide (Ctl peptide, 11-15). As negative controls, cells were cultured with medium supplemented with ECGS/ heparin only (5, 10, 15) . Tube formation was assayed after 4 hours by phase contrast microscopy and analyzed by measuring tube length per area using the ImagePro software. (B, C) Measures of tube formation of four fields per treatment (B) with 2 ng/ml VEGF-A, VEGF 165 , or VEGF 121 or (C) with equimolar concentrations of VEGF 165 (2.7 ng/ml) and/or VEGF 121 (2 ng/ml). Bars represent means ± standard error from two independent experiments. (D) Representative picture of PCR amplification of VEGF isoform in the presence or absence of C5a, VEGF-A, and/or PMX53 (as indicated). PCR amplification of β 2 -microglobulin was used as a control. (E, F) Densitometric analysis of transcript expression of VEFG 165 (E) and VEFG 121 (F) isoforms in HMECs treated with 2 nM C5a (black bars) or 2 ng/ml VEGF-A (gray bars) in medium or in the presence of 200 ng/ml PMX53 or control peptide (as indicated). VEGF isoform values were normalized to those of β 2 -microglobulin. Bars represent mean ± standard error from five independent experiments. supported the hypothesis that genetic C3 heterogeneity or deficiency impairs EC effector mechanisms in our model.
Pharmacological Inhibition of Complement Impairs VEGF 165 -dependent Function of Human ECs
To assess whether our in vivo findings were relevant to human physiology, we sought to study the effects of complement pharmacological inhibition on the human EC line HMEC. The C5aR is expressed on ECs and upregulated during inflammation [56, 57] . C5aR function can be inhibited by PMX53, a peptide that has been used in preclinical models to block neutrophil chemotaxis and clinically for treatment of rheumatoid arthritis and psoriasis [58] . We studied the effects of PMX53-mediated inhibition of C5aR on HMEC tube formation stimulated by VEGF-A (Figure 4 , A1 and B1, white bar) and the commercially available isoforms VEGF 165 (Figure 4 , A2 and B2, white bar) and VEGF 121 (Figure 4 , A3 and B3, white bar) compared to a control peptide (Figure 4, A11-15 and B, gray bars). PMX53 ( Figure 4B , black bars) impaired VEGF 165 -mediated tube formation (Figure 4 , A7, B2, and C ) but not VEGF 121 -mediated tube formation (Figure 4 , A8, B3, and C, ANOVA P > .05). PMX53 also impaired HMEC tube formation mediated by equimolar concentrations of VEGF 165 and VEGF 121 ( Figure 4C , P = .0232). As expected, treatment with control peptide did not affect tube formation. Of note, the difference observed between ECs activated by VEGF-A and treated with PMX53 was statistically significant but not meaningful (Figure 4 , A6 and B1, P = .0127 for VEGF-A vs VEGF-A/PMX53 but P = .9368 for VEGF-A/PMX53 vs VEGF-A/control peptide). These results suggested that C5aR inhibition selectively affected tube formation mediated by the VEGF 165 isoform.
C5a Promotes Tube Formation in a VEGF 165 -dependent Manner
To determine whether C5a had direct functional effects on ECs, HMECs were incubated with native C5a protein at 2 nM (20.8 ng/ml), which is within the plasma concentration range of C5a degradation product C5adesArg [59] . Tube formation similar to that mediated by VEGF-A and VEGF isoforms was observed (Figure 4 , A4 and B4, white bar), while PMX53 inhibited C5a-mediated tube formation (Figure 4 , A9 and B4, black bar, P < .0001). In addition, we found that PMX53 specifically inhibited the transcription of VEGF 165 (Figure 4 , D-E , P = .050) but not of VEGF 121 in C5a-treated HMEC cells (Figure 4 , D and F , P = .202). These results suggested a novel role for C5a in promoting EC tube formation through enhancing expression of VEGF 165 .
Genetic C3 Deficiency Affects the Expression of VEGF 164 Isoform
As experimental evidence pointed toward a role for C5a in VEGF 165 mediated activation of human ECs, we performed a comparative analysis of the expression of VEGF isoforms in mice that are complement deficient or complement sufficient. We analyzed the expression of the mouse homologues of human VEGF 121 and VEGF 165 that are mouse isoforms VEGF 120 and VEGF 164 , respectively, in the spleens, livers, and bone marrows isolated from WT and C3 KO mice. Figure 5 represents the relative expression of VEGF isoforms in WT and C3 KO mice after normalization against GAPDH. The expression of VEGF 164 , but not of VEGF120, was significantly reduced in C3
KO livers compared to WT livers ( Figure 5A , P = .048 and Figure 5B , P = .404).
Genetic C5aR Deficiency Impairs Tumor Growth and Neo-angiogenesis but Not Tumor Immune Infiltrate
To further assess the role of the C5a complement anaphylatoxin in ovarian cancer progression and angiogenesis, we crossed C5aR KO mice [35] with C57BL/6 TgMISIIR-TAg transgenic mice. We compared tumor development in 16- KO mice compared to Tg + C5aR WT littermates ( Figure 6C , P = .0004 and P < .0001, respectively). Additionally, MVD in tumors from Tg + C5aR KO mice was significantly decreased compared to Tg + C5aR HET mice ( Figure 6C , P < .0001). Finally, in vivo assays showed significantly impaired angiogenesis in C5aR KO mice compared to WT mice ( Figure 6D , P = .019). Collectively, these results supported the hypothesis that the tumor growth inhibition observed in mice with genetic complement deficiencies was associated with the alteration of EC function.
Discussion
Cancer establishment and progression is a multistep process of cumulative genetic alterations that enable cells to acquire uncontrolled growth. It has recently become clear, however, that to initiate cancer growth, genetically induced cell autonomy is often not sufficient, and an inflammatory reaction of the underlying stroma is required. The idea that chronic inflammation is intimately related to malignant transformation and tumor progression has been substantiated by human epidemiologic data and genetic experiments in mice, but the molecular and cellular determinants of these processes have not been well characterized. Here, we showed that deficiency of C3 or C5aR dramatically attenuates the tumor phenotype, abrogating tumor establishment and progression. Thus, complement activation is a critical component of the inflammatory process that supports oncogenedriven carcinogenesis. However, complement inactivation did not reduce the inflammatory infiltrate in tumors; we found no difference in the percentage of tumor-infiltrating leukocytes in Tg HET compared to Tg + C3 WT was in agreement with our previous findings in a mouse model of subcutaneous TC-1 cervical cancer, in which impaired growth of tumor cells was found when C5aR was blocked by an antagonist peptide [16] ; this effect was attributed to enhanced CD8 + T-cell infiltration in tumors and reduced recruitment of MDSCs [16] . Furthermore, we found no evidence for immune cell activation in Tg HET mice when compared to those fully sufficient in C3. These findings thus showed only indirect evidence of immune-mediated tumor rejection in these mice, through the decrease of immune regulatory cells or cytokines. Likewise, no evidence of immune-mediated tumor rejection was found in C5aR-hemizygous or C5aR-deficient mice, despite the dramatic attenuation of the tumor phenotype. + T cells was found. Thus, while our data support the notion that complement activation plays a critical role in activating tumor-infiltrating leukocytes, a process that is apparently essential to their tumor-promoting function, our data also indicate that increased activation of effector cells is not the major mechanism leading to suppressed ovarian oncogenesis in C3-hemizygous and C5aR-hemizygous or C5aR-deficient mice, and there is likely an alternate mechanism of tumor inhibition.
Because tumor-induced angiogenesis is largely dependent on VEGF, VEGF-neutralizing drugs are actively sought to inhibit cancer growth. Current VEGF-neutralizing agents inhibit tumor angiogenesis by blocking activation of VEGF receptors [60] , but agents have already been developed to selectively target VEGF isoforms. For example, Pegaptanib targets VEGF 165 for the treatment of AMD [61] , and the specific targeting of VEGF isoforms has been proposed as an effective cancer therapy [62] . We show here that the complement anaphylatoxin C5a present in the inflammatory milieu activates ECs and that the pharmacological inhibition of C5aR specifically targets the VEGF 165 isoform. Our results reveal a previously unknown role for complement activation in ovarian tumor vascularization and growth. However, these data should be considered within the context of our ovarian tumor model. While another study has shown that lack of C3 results in increased angiogenesis in a model of retinopathy of prematurity [63] , here it was found that C5a stimulation of ECs mediates angiogenic activity. Thus, the specific pathology may determine how complement influences different cell types, as well as the outcomes of that influence. The fact that small, unilateral ovarian tumors were present in 3 of 12 Tg + C3 KO mouse ovaries might be due to phenotype variability or incomplete penetrance not related to variations in genetic background or levels in gene expression [64, 65] . Because C3 KO mice produce C3 transcript and some of it can be translated into an inactive pro-form of C3 protein, one cannot eliminate the possibility that some active C3 can be produced in the Tg +
C3
KO mice through alternate splicing or processing. Alternatively, some unrelated factors could have also been differentially activated in these mice, such as the tumor microenvironment, or a different microbiome that could affect factors related to tumor growth, or even epigenetics. Future studies are needed to determine the molecular mechanisms underlying Tg + C3 KO phenotype variability. In conclusion, our findings have important implications for our understanding of the mechanisms underlying ovarian cancer development and for the design of future preventive and therapeutic strategies, such as combination therapies associating complement inhibitors with targeted anti-angiogenic therapeutic agents for the treatment of ovarian cancer. 
